The University of Southampton
University of Southampton Institutional Repository

Delayed mucosal anti-viral responses despite robust peripheral inflammation in fatal COVID-19.

Delayed mucosal anti-viral responses despite robust peripheral inflammation in fatal COVID-19.
Delayed mucosal anti-viral responses despite robust peripheral inflammation in fatal COVID-19.

BACKGROUND: While inflammatory and immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in peripheral blood are extensively described, responses at the upper respiratory mucosal site of initial infection are relatively poorly defined. We sought to identify mucosal cytokine/chemokine signatures that distinguished coronavirus disease 2019 (COVID-19) severity categories, and relate these to disease progression and peripheral inflammation.

METHODS: We measured 35 cytokines and chemokines in nasal samples from 274 patients hospitalized with COVID-19. Analysis considered the timing of sampling during disease, as either the early (0-5 days after symptom onset) or late (6-20 days after symptom onset) phase.

RESULTS: Patients that survived severe COVID-19 showed interferon (IFN)-dominated mucosal immune responses (IFN-γ, CXCL10, and CXCL13) early in infection. These early mucosal responses were absent in patients who would progress to fatal disease despite equivalent SARS-CoV-2 viral load. Mucosal inflammation in later disease was dominated by interleukin 2 (IL-2), IL-10, IFN-γ, and IL-12p70, which scaled with severity but did not differentiate patients who would survive or succumb to disease. Cytokines and chemokines in the mucosa showed distinctions from responses evident in the peripheral blood, particularly during fatal disease.

CONCLUSIONS: Defective early mucosal antiviral responses anticipate fatal COVID-19 but are not associated with viral load. Early mucosal immune responses may define the trajectory of severe COVID-19.

Humans, COVID-19/immunology, Male, Female, Middle Aged, SARS-CoV-2/immunology, Cytokines/blood, Aged, Inflammation/immunology, Immunity, Mucosal, Viral Load, Adult, Chemokines/blood, Severity of Illness Index, Nasal Mucosa/immunology
0022-1899
e17-e29
Sidhu, Jasmin K
69eaff4a-d321-4609-a299-d77be36de910
Siggins, Matthew K
92337ac7-6072-480e-b915-26a6449d9599
Liew, Felicity
e49e3c8f-853a-4876-8cd8-739f39d8b74d
Russell, Clark D
80352f5e-cda1-4635-b0ca-c3c920c67590
Uruchurtu, Ashley S S
6063d5e3-a3dd-4b35-899f-5d12a3931d36
Davis, Christopher
8c8d7743-dbbe-498f-a0da-7377102b01fc
Turtle, Lance
46a79918-7fd1-4002-84d5-bc3bd0b26632
Moore, Shona C
b2fd0970-e2be-4d9f-a31c-ed29cc8762b5
Hardwick, Hayley E
5f11e28f-495e-43ff-bf3c-7388f0619684
Oosthuyzen, Wilna
2bda64bc-0e23-4399-9c19-84d4fd133d53
Thomson, Emma C
c02a878f-f60f-4017-821c-962e98c01a8b
Semple, Malcolm G
c4523cd6-7b9b-4287-a176-e12be58d6557
Baillie, J Kenneth
a08f7c7f-62a3-44ea-af0e-aa5f1ffde00c
Openshaw, Peter J M
4e1ec99b-8f41-4740-be78-a57b2361d483
Thwaites, Ryan S
0cf76282-a7ed-4361-8a93-78ca5e7127fc
Dushianthan, Ahilanandan
013692a2-cf26-4278-80bd-9d8fcdb17751
ISARIC4C Investigators
Sidhu, Jasmin K
69eaff4a-d321-4609-a299-d77be36de910
Siggins, Matthew K
92337ac7-6072-480e-b915-26a6449d9599
Liew, Felicity
e49e3c8f-853a-4876-8cd8-739f39d8b74d
Russell, Clark D
80352f5e-cda1-4635-b0ca-c3c920c67590
Uruchurtu, Ashley S S
6063d5e3-a3dd-4b35-899f-5d12a3931d36
Davis, Christopher
8c8d7743-dbbe-498f-a0da-7377102b01fc
Turtle, Lance
46a79918-7fd1-4002-84d5-bc3bd0b26632
Moore, Shona C
b2fd0970-e2be-4d9f-a31c-ed29cc8762b5
Hardwick, Hayley E
5f11e28f-495e-43ff-bf3c-7388f0619684
Oosthuyzen, Wilna
2bda64bc-0e23-4399-9c19-84d4fd133d53
Thomson, Emma C
c02a878f-f60f-4017-821c-962e98c01a8b
Semple, Malcolm G
c4523cd6-7b9b-4287-a176-e12be58d6557
Baillie, J Kenneth
a08f7c7f-62a3-44ea-af0e-aa5f1ffde00c
Openshaw, Peter J M
4e1ec99b-8f41-4740-be78-a57b2361d483
Thwaites, Ryan S
0cf76282-a7ed-4361-8a93-78ca5e7127fc
Dushianthan, Ahilanandan
013692a2-cf26-4278-80bd-9d8fcdb17751

Sidhu, Jasmin K, Siggins, Matthew K, Liew, Felicity, Russell, Clark D, Uruchurtu, Ashley S S, Davis, Christopher, Turtle, Lance, Moore, Shona C, Hardwick, Hayley E, Oosthuyzen, Wilna, Thomson, Emma C, Semple, Malcolm G, Baillie, J Kenneth, Openshaw, Peter J M and Thwaites, Ryan S , ISARIC4C Investigators (2024) Delayed mucosal anti-viral responses despite robust peripheral inflammation in fatal COVID-19. The Journal of Infectious Diseases, 230 (1), e17-e29. (doi:10.1093/infdis/jiad590).

Record type: Article

Abstract

BACKGROUND: While inflammatory and immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in peripheral blood are extensively described, responses at the upper respiratory mucosal site of initial infection are relatively poorly defined. We sought to identify mucosal cytokine/chemokine signatures that distinguished coronavirus disease 2019 (COVID-19) severity categories, and relate these to disease progression and peripheral inflammation.

METHODS: We measured 35 cytokines and chemokines in nasal samples from 274 patients hospitalized with COVID-19. Analysis considered the timing of sampling during disease, as either the early (0-5 days after symptom onset) or late (6-20 days after symptom onset) phase.

RESULTS: Patients that survived severe COVID-19 showed interferon (IFN)-dominated mucosal immune responses (IFN-γ, CXCL10, and CXCL13) early in infection. These early mucosal responses were absent in patients who would progress to fatal disease despite equivalent SARS-CoV-2 viral load. Mucosal inflammation in later disease was dominated by interleukin 2 (IL-2), IL-10, IFN-γ, and IL-12p70, which scaled with severity but did not differentiate patients who would survive or succumb to disease. Cytokines and chemokines in the mucosa showed distinctions from responses evident in the peripheral blood, particularly during fatal disease.

CONCLUSIONS: Defective early mucosal antiviral responses anticipate fatal COVID-19 but are not associated with viral load. Early mucosal immune responses may define the trajectory of severe COVID-19.

This record has no associated files available for download.

More information

Published date: 25 July 2024
Additional Information: © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Keywords: Humans, COVID-19/immunology, Male, Female, Middle Aged, SARS-CoV-2/immunology, Cytokines/blood, Aged, Inflammation/immunology, Immunity, Mucosal, Viral Load, Adult, Chemokines/blood, Severity of Illness Index, Nasal Mucosa/immunology

Identifiers

Local EPrints ID: 493718
URI: http://eprints.soton.ac.uk/id/eprint/493718
ISSN: 0022-1899
PURE UUID: a3fe4cbc-6f33-462b-867b-b2954275a55d
ORCID for Ahilanandan Dushianthan: ORCID iD orcid.org/0000-0002-0165-3359

Catalogue record

Date deposited: 11 Sep 2024 17:12
Last modified: 12 Sep 2024 01:56

Export record

Altmetrics

Contributors

Author: Jasmin K Sidhu
Author: Matthew K Siggins
Author: Felicity Liew
Author: Clark D Russell
Author: Ashley S S Uruchurtu
Author: Christopher Davis
Author: Lance Turtle
Author: Shona C Moore
Author: Hayley E Hardwick
Author: Wilna Oosthuyzen
Author: Emma C Thomson
Author: Malcolm G Semple
Author: J Kenneth Baillie
Author: Peter J M Openshaw
Author: Ryan S Thwaites
Author: Ahilanandan Dushianthan ORCID iD
Corporate Author: ISARIC4C Investigators

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×